S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Sarah A. Richman,Selene Nunez-Cruz,Babak Moghimi,Lucy Z. Li,Zachary Gershenson,Zissimos Mourelatos,David M. Barrett,Stephan A. Grupp,Michael C. Milone +8 more
TL;DR: The fatal neurotoxicity of GD2-specific CAR T-cell therapy observed in these studies suggests that GD2 may be a difficult target antigen forCAR T- cell therapy without additional strategies that can control CART-cell function within the CNS.
Journal ArticleDOI
Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells
Saba Ghassemi,Selene Nunez-Cruz,Roddy S. O’Connor,Joseph A. Fraietta,Prachi R. Patel,John Scholler,David M. Barrett,Stefan Lundh,Megan M. Davis,Felipe Bedoya,Changfeng Zhang,John Leferovich,Simon F. Lacey,Bruce L. Levine,Stephan A. Grupp,Carl H. June,J. Joseph Melenhorst,Michael C. Milone +17 more
TL;DR: It is demonstrated that T cells with a CAR-targeting CD19 (CART19) exhibited less differentiation and enhanced effector function in vitro when harvested from cultures at earlier compared with later timepoints, and the antileukemic activity inversely correlated with ex vivo culture time.
Journal ArticleDOI
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Michael Boyiadzis,Madhav V. Dhodapkar,Renier J. Brentjens,James N. Kochenderfer,Sattva S. Neelapu,Marcela V. Maus,David L. Porter,David G. Maloney,Stephan A. Grupp,Stephan A. Grupp,Crystal L. Mackall,Carl H. June,Michael R. Bishop +12 more
TL;DR: This review provides expert perspective on the significance and clinical considerations of CAR T cell therapies in order to provide timely information to clinicians about this revolutionary new therapeutic class.
Journal ArticleDOI
IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients
Michael A. Pulsipher,Christopher S. Carlson,Bryan Langholz,Donna A. Wall,Kirk R. Schultz,Nancy Bunin,Ilan R. Kirsch,Julie M. Gastier-Foster,Michael J. Borowitz,Cindy Desmarais,David Williamson,Michael Kalos,Stephan A. Grupp +12 more
TL;DR: Post-HCT NGS-MRD detection is highly predictive of relapse and survival, suggesting a role for this technique in defining patients early who would be eligible for post- HCT interventions.
Journal ArticleDOI
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction
Nathan Singh,Yong Gu Lee,Olga Shestova,Pranali Ravikumar,Katharina E. Hayer,Seok Jae Hong,Xueqing Maggie Lu,Raymone Pajarillo,Sangya Agarwal,Shunichiro Kuramitsu,Elena Orlando,Karen Thudium Mueller,Charly R. Good,Shelley L. Berger,Ophir Shalem,Ophir Shalem,Matthew D. Weitzman,Matthew D. Weitzman,Noelle V. Frey,Shannon L. Maude,Stephan A. Grupp,Carl H. June,Saar Gill,Marco Ruella +23 more
TL;DR: It is suggested that inherent dysregulation of death receptor signaling in ALL directly leads to CAR T cell failure by impairing T cell cytotoxicity and promoting progressiveCAR T cell dysfunction.